drugset / Trial / NCT04794101

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04794101 ↗

Phase 3 Active not recruiting 97 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Timeline

Start
2020-12-04
Primary completion
2029-09-20
Completion
2029-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AAV5-hRKp.RPGR Gene therapy (AAV / viral vector) — Subcutaneous

Indications